Myonex, LLC, a prominent player in the biotechnology sector, is headquartered in the United States and operates extensively across North America and Europe. Founded in 2010, the company has established itself as a leader in developing innovative solutions for the pharmaceutical and healthcare industries. Myonex is renowned for its cutting-edge drug delivery systems and advanced therapeutic technologies, which are designed to enhance patient outcomes and streamline treatment processes. With a commitment to research and development, Myonex has achieved significant milestones, including several patents for its proprietary technologies. The company’s unique approach to drug formulation and delivery sets it apart in a competitive market, positioning it as a trusted partner for healthcare providers and pharmaceutical companies alike. Myonex continues to drive advancements in biotechnology, contributing to the evolution of modern medicine.
How does Myonex, LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Myonex, LLC's score of 18 is lower than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Myonex, LLC, headquartered in the US, has set ambitious climate commitments despite not having specific carbon emissions data available. The company has established near-term targets to reduce its absolute Scope 1 and Scope 2 greenhouse gas emissions by approximately 63% by the year 2035, using 2023 as the base year. This target aligns with the science-based criteria necessary to limit global warming to 1.5°C, reflecting a commitment to sustainable practices within the specialized consumer services sector. Additionally, Myonex is dedicated to measuring and reducing its Scope 3 emissions, further enhancing its climate strategy. These initiatives demonstrate Myonex's proactive approach to addressing climate change and contributing to a more sustainable future.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Myonex, LLC has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

